Can a sharp beam of radiation tame spreading thyroid cancer?
NCT ID NCT07755423
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial is testing whether a precise, high-dose form of radiation called stereotactic body radiotherapy (SBRT) can control distant metastases in people with stage IV thyroid cancer. The study enrolls patients with up to five metastatic lesions who have already tried systemic therapy. The goal is to see if SBRT can stop the cancer from growing, potentially offering a new treatment option for this advanced stage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic body radiotherapy (SBRT), a precise high-dose radiation technique
- What this could lead to
- If successful, this could offer a new way to control metastatic thyroid cancer, potentially delaying disease progression and improving quality of life for patients who have exhausted systemic options.
- What could go wrong
- This is a small phase II study, so results may not be definitive. SBRT can cause side effects like fatigue or damage to nearby organs, and not all patients may benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.